“Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial”. 2023. SKIN The Journal of Cutaneous Medicine 7 (4): s218. https://doi.org/10.25251/skin.7.supp.218.